Evidence map›Paper›PMID 39772240›Full record

ArticleViruses2024

A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques.

Elizabeth E Zumbrun, Carly B Garvey, Jay B Wells, Ginger C Lynn, Sean A Van Tongeren, Jesse T Steffens, Kelly S Wetzel, Darrell L Wetzel, Heather L Esham, Nicole L Garza and 30 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Elizabeth E ZumbrunUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Carly B GarveyUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jay B WellsUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Ginger C LynnUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Sean A Van TongerenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jesse T SteffensUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Kelly S WetzelUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Darrell L WetzelUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Heather L EshamUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Nicole L GarzaUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Eric D LeeUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jennifer L ScruggsUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Franco D RossiUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Elizabeth S BrownUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jessica M WeidnerUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Laura M GombaUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Kristan A O'BrienUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Alexandra N JayUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.ORCID 0000-0002-5246-6940
Xiankun ZengUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Kristen S AkersUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Paul A KallgrenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Ethan EnglundUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
J Matthew MeinigUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jeffrey R KugelmanUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Joshua L MooreUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Holly A BloomfieldUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Sarah L NorrisUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.ORCID 0000-0002-5393-6430
Tameka BryanPharPoint Research, Inc., Wilmington, NC 28401, USA.
Christie H ScheuerellLabcorp Early Development Laboratories, Madison, WI 53704, USA.
Jesse WaltersLabcorp Early Development Laboratories, Madison, WI 53704, USA.
Nevena MollovaGilead Sciences, Inc., Foster City, CA 94404, USA.
Christiana BlairGilead Sciences, Inc., Foster City, CA 94404, USA.
Darius BabusisGilead Sciences, Inc., Foster City, CA 94404, USA.ORCID 0000-0001-5599-1671
Tomas CihlarGilead Sciences, Inc., Foster City, CA 94404, USA.
Danielle P PorterGilead Sciences, Inc., Foster City, CA 94404, USA.
Bali SinghGilead Sciences, Inc., Foster City, CA 94404, USA.
Charlotte HedskogGilead Sciences, Inc., Foster City, CA 94404, USA.
Sina BavariUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Travis K WarrenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Roy BannisterGilead Sciences, Inc., Foster City, CA 94404, USA.

Funding

Studies at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) were supported by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) through the Medical Countermeasures Systems W81XWH-16-0472
6 · The paper itself

Abstract

Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here, we characterize the efficacy of multiple intravenous RDV dosing regimens on survival of rhesus macaques 42 days after intramuscular EBOV exposure. Thirty rhesus macaques underwent surgical implantation of telemetry devices for the fine-scale monitoring of body temperature and activity, as well as central venous catheters, to enable treatment administration and blood collection. Treatment, consisting of a loading dose of RDV followed by once-daily maintenance doses for 11 days, was initiated 4 days after virus exposure when all animals were exhibiting disease signs consistent with incipient EBOV disease as well as quantifiable levels of EBOV RNA in plasma. In the RDV treatment groups receiving loading/maintenance doses of 5/2.5 mg/kg, 10/5 mg/kg, and 20/10 mg/kg, a total of 6 of 8 (75%), 7 of 8 (87.5%), and 5 of 7 (71.4%) animals survived, respectively. In the vehicle control group, one of seven animals (14.3%) survived. The improved survival rate compared to the control group was statistically significant only for the 10/5 mg/kg RDV treatment group. This treatment regimen also resulted in a significantly lower systemic viral load compared to the vehicle control after a single RDV treatment. All three RDV regimens produced a significantly lower systemic viral load after two treatments. For most animals, RDV treatment, regardless of dose, resulted in the amelioration of many of the clinical-pathological changes associated with EBOV disease in this model.

Indexed as

Adenosine MonophosphateAlanineAntiviral AgentsEbolavirusHemorrhagic Fever, EbolaMacaca mulattaAnimalsDisease Models, AnimalFemaleMaleRandom AllocationViral LoadAdenosine MonophosphateAlanineAntiviral AgentsremdesivirEbola virusfilovirusGS-5734nonhuman primateRDVremdesivirrhesus macaqueVeklury

Identifiers

PMID39772240
PMCPMC11680158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.